Chelation in metal intoxication-Principles and paradigms

被引:128
作者
Aaseth, Jan [1 ]
Skaug, Marit Aralt [2 ]
Cao, Yang [3 ]
Andersen, Ole [4 ]
机构
[1] Innlandet Hosp Trust, Kongsvinger Hosp Div, Kongsvinger, Norway
[2] Hedmark Univ Coll, Fac Publ Hlth, N-2418 Elverum, Norway
[3] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden
[4] Roskilde Univ, Dept Sci Syst & Models, Roskilde, Denmark
关键词
DMSA; DMPS; Deferiprone; Deferasirox; Deferoxamine; PLACEBO-CONTROLLED TRIAL; THALASSEMIA MAJOR; IRON OVERLOAD; MESO-2,3-DIMERCAPTOSUCCINIC ACID; 2,3-DIMERCAPTOSUCCINIC ACID; AMINOSALICYLIC ACID; CHRONIC ARSENICOSIS; CARDIAC IRON; THERAPY; EFFICACY;
D O I
10.1016/j.jtemb.2014.10.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The present review provides an update of the general principles for the investigation and use of chelating agents in the treatment of intoxications by metals. The clinical use of the old chelators EDTA (ethylenediamine tetraacetate) and BAL (2,3-dimercaptopropanol) is now limited due to the inconvenience of parenteral administration, their own toxicity and tendency to increase the neurotoxi city of several metals. The hydrophilic dithiol chelators DMSA (meso-2,3-dimercaptosuccinic acid) and DMPS (2,3-dimercaptopropanesulphonate) are less toxic and more efficient than BAL in the clinical treatment of heavy metal poisoning, and available as capsules for oral use. In copper overload, DMSA appears to be a potent antidote, although D-penicillamine is still widely used. In the chelation of iron, the thiols are inefficient, since iron has higher affinity for ligands with nitrogen and oxygen, but the new oral iron antidotes deferiprone and desferasirox have entered into the clinical arena. Comparisons of these agents and deferoxamine infusions are in progress. General principles for research and development of new chelators are briefly outlined in this review. (C) 2014 Elsevier GmbH. All rights reserved.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 82 条
[1]
RECENT ADVANCE IN THE THERAPY OF METAL POISONINGS WITH CHELATING-AGENTS [J].
AASETH, J .
HUMAN TOXICOLOGY, 1983, 2 (02) :257-272
[2]
AASETH J, 1973, ACTA PHARMACOL TOX, V32, P430
[3]
Principles and recent developments in chelation treatment of metal intoxication [J].
Andersen, O .
CHEMICAL REVIEWS, 1999, 99 (09) :2683-2710
[4]
Molecular mechanisms of in vivo metal chelation:: Implications for clinical treatment of metal intoxications [J].
Andersen, O ;
Aaseth, J .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2002, 110 :887-890
[5]
Andersen O, 2005, METALS ESSENTIALITY, P48
[6]
DMSA, DMPS, AND DMPA - AS ARSENIC ANTIDOTES [J].
APOSHIAN, HV ;
CARTER, DE ;
HOOVER, TD ;
HSU, CA ;
MAIORINO, RM ;
STINE, E .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1984, 4 (02) :S58-S70
[7]
The neuropathogenesis of mercury toxicity [J].
Aschner, M ;
Walker, S .
MOLECULAR PSYCHIATRY, 2002, 7 (Suppl 2) :S40-S41
[8]
BASINGER MA, 1981, RES COMMUN CHEM PATH, V32, P355
[9]
INCREASED UPTAKE OF MERCURY IN MOUSE BRAIN CAUSED BY 2,3-DIMERCAPTOPROPANOL [J].
BERLIN, M ;
ULLREBG, S .
NATURE, 1963, 197 (486) :84-&
[10]
Autism: a novel form of mercury poisoning [J].
Bernard, S ;
Enayati, A ;
Redwood, L ;
Roger, H ;
Binstock, T .
MEDICAL HYPOTHESES, 2001, 56 (04) :462-471